We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Bodisen | BODI | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 6.00 | 01:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 6.00 | 6.00 |
| Top Posts |
|---|
Posted at 13/4/2011 02:00 by mattjos interesting 1st Q results from peer Yongye:Yongye International, Inc. (NASDAQ: YONG), a leading agricultural nutrient company in China ("Yongye" or the "Company"), today announced preliminary financial results for the first quarter of 2011. The Company's revenues for the three months ended March 31, 2011, were $50.2 million, more than double last year's first quarter revenues of $24.9 million. The significant increase in revenues was driven by higher demand for the Company's products in its traditional markets, and growth in several new markets. In addition, after the acquisition of the Hebei customer list in July 2010, the Company is selling its products at a higher price directly to lower level distributors in Hebei, which is Yongye's largest regional market in China. As of March 31, 2011, Yongye had 26,006 independently-owned branded stores in its network, compared to 24,036 stores at the end of 2010. In addition, during the first quarter of 2011, the Company achieved positive cash flow from operations. For full year 2011, the Company continues to expect revenues of between $315 million and $325 million, representing an increase of 47.1% and 51.8% over 2010's revenue of $214.1 million. The Company expects adjusted net income attributable to Yongye, which excludes non-cash expenses related to share-based compensation for management and independent directors, the amortization of the acquired Hebei customer list, and a change in the fair value of derivative liabilities, of between $80 million and $82 million, representing an increase of between 47.9% and 51.6% over 2010 adjusted net income attributable to Yongye of $54.1 million. The Company has a year-end target of at least 30,000 for the number of independently-owned, branded stores selling Yongye's Shengmingsu products. "We are pleased with our first quarter sales and cash flow results," stated Mr. Zishen Wu, Chairman and Chief Executive Officer. "As many of our investors know, our first and fourth quarters are seasonally our slowest. Nevertheless, we were able to achieve strong sales growth as a result of continued demand for our Shengmingsu agricultural nutrient products from Chinese farmers in both new and existing provinces. Also of importance, we achieved positive cash flow from operations as a result of our improved working capital management, while more than doubling our sales year-over-year." Mr. Wu concluded, "Our management team and board of directors are committed to enhancing shareholder value and are confident in the long-term health and future financial performance of our business. Based on current market prices, we believe that our shares are presently undervalued in the marketplace. Our board of directors is contemplating various alternatives to address this issue and will make an announcement as soon as the board determines the appropriate course of action." The results announced in this press release are unaudited. The Company plans to release its first quarter 2011 financial results in May 2011. |
Posted at 30/3/2011 15:16 by mattjos i did .. on this thread & on my thread.i seem a lone voice at present ... either i've got it all wrong here or one day later this autumn the crowds might decide to arrive. till then i wait to see how the next few quarters go for the company and quite what are the intentios of the usa investor |
Posted at 01/8/2007 13:00 by cimbom RNS Number:3160BBodisen Biotech Inc 01 August 2007 1 August 2007 Bodisen Biotech, Inc. ("Bodisen" or the "Company") Contract Win Bodisen Biotech, Inc. (the "Company") (London AIM: BODI; OTC Pink Sheets: BBCZ; website: www.bodisen.com) today announces its first export contract win. The Company announces it has signed a contract with RADUGA Co., Ltd. through Aoshen Imports and Exports Co., Ltd in the city of Huhehaote in the Inner Mongolia Autonomous area for export to customers in Russia. This contract is for approximately 2.3 million RMB in products and represents the first international export order for the Company. Management Appointment The Company also announces that Ms Junyan Tong, age 36, has been appointed to serve as the Company's Chief Financial Officer Ms Tong has previously served as the Company's Assistant Chief Financial Officer since 2005. This is not a main board appointment. From 1998 -2002, Ms Tong was Chief Financial Officer of Shenzhen Rongxun Industry Co., Ltd., and between 1995- 1998, Ms Tong served as Financial Manager of Guangdong Zhongyunhui Electric Co., Ltd. About Bodisen Biotech, Inc. Bodisen Biotech, Inc. is a leading manufacturer of liquid and organic compound fertilizers, pesticides, insecticides and agricultural raw materials certified by the Petroleum Chemical Industry Administrative office of China (Chemical Petroleum Production Administrative Bureau), Shaanxi provincial government and Chinese government. The Company is headquartered in Shaanxi province and is a Delaware corporation. The Company's environmentally friendly "green" products have been proven to improve soil and plant quality and increase crop yields. Safe Harbor Statement This press release may contain forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on the current expectations or beliefs of Bodisen Biotech, Inc. management and are subject to a number of factors and uncertainties, and the outcome of events may differ materially from those described in the forward-looking statements. Enquiries: Bodisen Investor Relations Scott King - 001 219 939 3073 info@bodisen.com Charles Stanley Securities (Nominated Adviser) Rick Thompson / Philip Davies / Carl Holmes - 0207 149 6000 This information is provided by RNS The company news service from the London Stock Exchange END NRAUAOARBRRWRAR |
Posted at 01/5/2007 13:47 by leighbarton Any comment on the results is outweighed by the Amex delisting and resultant litigation proceedings. A number of points from the filing:Wey got massive compensation, previously undisclosed from the various placings. $5m from the AIM listing alone. Why? Part of the proceeds for the placing were to be used to build a factory in the NE. They subsequently decided not to do this. Why? what has the money been used for instead? The company is making loans left right and centre. Huge advances to its suppliers, even larger ones to its customers. This now has risen to $18m. Remember this is to pure peasant farmers. No issue when things are going well, but should there be a drought then these farmers will have no reserves to honour their commitments. At $7m I was fairly relaxed about this, but this has soared since the interims. It would be good to have a geographic analysis of where these loans are distributed to see the exposure the company has to drought prone regions. Corporate Governance is clearly an issue here with previously undisclosed dealings by the management and founding investors, distributions of which were made from a reserve over the last financial period. 738,000 shares are still o/s in this regard (shares unclaimed by fouding investors). What's this all about. All these factors I think cloud what otherwise look a healthy set of numbers. The risk factor I think is just too high, with the possibility that the company could still take a hammering. Not tempted back in in spite of (maybe because of) the recovery in share price. A real shame but it does highlight the potential risks of investing in Chinese entities. Let's hope BODI is a one off, and got away with it because it did reverse into the market as opposed to going through the rigours of an IPO. |
Posted at 12/2/2007 15:49 by cimbom Ms. Qiong Wang, Director and Former CEO of Bodisen, Won the Award of 'China Pioneering Talent of 2006'PrintE-mailDisable live quotesRSSDigg itDel.icio.us Last Update: 12:08 PM ET Feb 8, 2007 SHAANXI, China, Feb 8, 2007 (PrimeNewswire via COMTEX) -- Bodisen Biotech, Inc. (BBC : bodisen biotech inc com News , chart, profile, more Last: 4.24-0.06-1.40% 10:28am 02/12/2007 Delayed quote dataAdd to portfolio Analyst Create alertInsider Discuss Financials Sponsored by: BBC4.24, -0.06, -1.4%) (London:BOD) (website: today announced that Ms. Qiong Wang, director and former CEO, won the award of "China Pioneering Talent of 2006." The grand opening of "China's Top Ten Series Talents of 2006" was jointly hosted on February 4, 2007 by the Educational, Scientific, Cultural, Healthcare and Sports Committee of the National Chinese People's Political Consultative Commission, the U.N. Educational, Scientific, and Cultural Organization (UNESCO), The China National Chamber of Industry & Commerce, The Association of China's International Friendship, etc. Deputy Commissioners of the China National People's Congress, Xu Jialu, and Wuyunqimuge, Vice Chairpersons of China National Political Consultative Committee, Mr. Sun Fulin, Mr. Abulaiti Abudurexiti, Mr. Zhou Tienong, and former defense minister, Mr Chi Haotian attended the ceremony and delivered awards to the winners. Ms. Qiong Wang, director and former CEO of Bodisen Biotech Inc. earned the award of "Pioneering Talent." The criteria for the "China's Top Ten Series Talents" were "innovation, perfection, model," advocating the principles of people as the ultimate purpose for reforms, developments, and renaissance. The board of review consists of officials, experts, media reps, and masses reps. The goal is to select the best candidates from different industries representing the greatest potential in China. This is a widely watched national honor, which is in its second annual round. The ten series of talents refer to innovation, talents, commerce, integrity, education, science & technology, management, construction, and charisma. Each series will see ten winners so that in total we have 100 winners from all over China here. Bodisen Biotech Inc. achieved great success in a few years under the leadership of Ms Qiong Wang. Qiong Wang is the only entrepreneur from Shaanxi to earn this honor, which is her second national honor in The Great People's Congress Hall after her award of "China Pioneering Personality." About Bodisen Biotech, Inc. Bodisen Biotech Inc. is a leading manufacturer of liquid and organic compound fertilizers, pesticides, insecticides and agricultural raw materials certified by the Petroleum Chemical Industry Administrative office of China (Chemical Petroleum Production Administrative Bureau), Shaanxi provincial government and Chinese government. Ranked the 16th fastest growing company in China by Forbes China in January 2006, the Company is headquartered in Shaanxi province and is a Delaware corporation. The Company's environmentally friendly "green" products have been proven to improve soil and plant quality, and increase crop yields. Safe Harbor Statement This press release may contain forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on the current expectations or beliefs of Bodisen Biotech, Inc. management and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. This news release was distributed by PrimeNewswire, www.primenewswire.co SOURCE: Bodisen Biotech Inc. Bodisen Biotech, Inc. Investor Relations: Hong Zhu (212) 302-1666 info@bodisen.com |
Posted at 16/11/2006 18:06 by leighbarton Cimbom, I'm still in but will look closely to where the US closes tonight. I agree nothing has changed with the company's financials, but that is not what is now at issue. It is a question of trust. This whole issue would not have flaired up nearly so badly if it had not been for that 3rd Qtr update. Had they kept stum and just published the results then the Amex investigation would have looked historical (ie their dealings with dodgy dealer) and so not nearly so relevant to what is going on today. But the fact they gave a bullish update that Greenberg slated, and which came out to be anything but bullish not only gives credence to Greenberg's claims but also means that Amex is not just dealing with historical stuff. How many of the original investors cashed out on the back of that update?I can't make up my mind if this is a cultural thing or it is per Greenberg and that the whole thing is corrupt. It sure has a nasty aroma about it though. What it does mean that the market's trust with this company is blown. If they give a bullish update for the 4th Qtr whose going to believe it? If their 4th Qtr numbers are stunning there will still be grounds for people to attack it because of the high account receivables - who knows what they are hiding there if you no longer trust the company? If you really then start to worry - what about all those advance payments to supplier companies - are they strictly kosher and to unrelated third parties? Large sums are involved and you can see how the whole thing could start unravelling. (Not that I am stating there is anything wrong with those contracts, but just how the business model could give rise to suspicions once trust is out of the equation). I am not sure what it is going to take to get recovery in the share price from this point. I think probably nothing short of their paying dividends but they are in no position to do that as their business model is cash intensive. I am normally absolutely rigid about getting out of a company as soon as there is any official indication of wrong doing - lesson learned, never to go against that rule even if you think the financials will pull it round! That decision has cost me £8k to date and at the moment the US seems to have no floor as to how far this will go. re class action I have registered with the address that Miami posted yesterday but have heard nothing back. I don't agree with it in principle as I went into this with my eyes wide open. However as an investor it is good to have an inside track as to how serious these guys are and to get a feel for how realistic a chance of success they have. With the amount of losses people have suffered (from a peak of $20 to $4 today), if the company is ordered to make restitution it could be enough to sink them in spite of their financials. What then will that do to the PRC's govt view on Foreign ownership? As I said before this is going to get alot messier before we start to see any kind of recovery. |
Posted at 16/11/2006 17:45 by zho 16.11.2006 - RC Group makes its markEveryone has been knocking the UK's relatively lightly regulated AIM market recently but part of this is due to its runaway success in attracting exciting young companies from all over the World. There have been so many new issues over the last 12 months that many are now referring to " AIM Fatigue " with brokers' clients simply unable to absorb any new offerings. The other reason why investors are a little more circumspect is the fact that so many foreign companies do not quite have the same grasp of corporate governance as their UK counterparts. Just in the last few days, BODISEN BIOTECH, the Chinese fertiliser manufacturer, which we have tipped several times, has been instructed by the American Stock Exchange to sever links with a somewhat dubious corporate finance consultancy in Oklahoma. This has sent the shareprice into a tailspin despite quarterly figures announced the next day showing that profits for the first 9 months are ahead by another breathtaking 75 %. BODI should earn around 40p for the full year leaving the shares at 300p selling at a mere 7.5 times earnings. This is silly money for a company growing at such a rapid rate and the shares should bounce back strongly if, as we suspect, the company's minor misdemeanour is proved to be more down to naivity than anything more sinister. The Bodisen experience underlines what a double - edged sword the AIM market can be at times. AIM investors are spoilt for choice with so many of the World's fastest growing companies to choose from ( Bodisen for instance is ranked by Forbes as the 16th fastest growing company in China )but the downside is that things do not operate on the far side of the globe quite the same as they do in London . Those who are prepared to take the rough with the smooth and accept the added risk involved have a number of real AIM bargains from which to choose. Take, for example, the HongKong based RC Group who manufacture biometric security devices involving fingerprint and facial recognition systems. Because of the way the World is nowadays, this market is forecast to grow from $ 2.1 billion this year to $ 5.7 billion in 2010 and RCG is on course to grab a healthy slice of this cake via vigorous organic growth and an equally brisk acquisition programme. The latest interim figures speak for themselves with organic revenues up by over 200% and acquired revenues adding a further sizeable chunk leaving a grand total of 371%. Pretax profit growth was just as impressive - up 357%. Brokers, Corporate Synergy, are forecasting earnings per share of about 7 p for the full year suggesting that the shares, which have already doubled this year to 71p, are still only selling on a price earnings multiple of 10. There should also be a small but fast growing dividend payout to anticipate. If RCG was headquartered in the UK, you would probably expect to pay nearer 20 times earnings for this one - you pays your money and takes your choice ! You can read all about RC Group's leading edge technology and products at www.rcg.tv. |
Posted at 10/10/2006 17:16 by miamisteve Spoke to investors relations pr firm today.While they don'y seem overly clued up on the business the lady was not too happy about the new york post article. She confirmed that the large sells were from seed investors whose lock-in had expired. |
Posted at 03/10/2006 14:16 by cimbom This article is one of the few articles which tell the story as it is with an unbiased view.Bodisen Biotech Inc.: Chinese Fertilizer Company's honeymoon on AIM, NYSE hits a bump By William Foss The 28th of March was a big day for Bodisen Biotech. The company's maiden results since initiating a primary listing in New York and a secondary listing in London were closely watched by many pundits on both sides of the Atlantic to see how the fertiliser company faired. Compared to 2004, revenues grew 91% to USD $31 million and net income was up 75% to USD $8.8 million. Furthermore, the order book for 2006 is already greater than 2005 and the company has also received an additional 2 year leave from paying Income Tax. Not to mention that during 2005, Bodisen successfully doubled it's organic fertiliser capacity and also acquired a strategic stake in China Natural Gas Company (OTCBB: CHNG). Since moving onto the New York & London boards, Bodisen's market capitalisation has reflected an expectation of strong growth going forward, and the company didn't disappoint. Bodisen currently has over 60 products on offer to farmers in over 20 provinces in China. The company boasts that its organic fertilizers are competitvely priced to chemical alternatives, but also offer up to 35% higher crop yields, improved soil conditions and also allows farmers to increase their own selling price by having their produce certified as organic green foods. Bodisen intends to aggressively expand market reach in China, and has also used the increased awareness from the dual listings as a way to start negotiations to form joint ventures with companies in the west. Perhaps the most compelling statistic of all supplied by Bodisen, is the fact that of the 1.3 billion people living in China, 900 million are farmers whose livelihood is dependent on crop yields - a massive market. Bodisen currently generates 67% of it's revenues from organic fertilisers - over the next 5 years organic fertilisers are expected to increase in use from 6% to 20% of the overall USD $25 billion Chinese fertiliser market. So why have the shares plunged this morning? Until this weekend the company had enjoyed a positive start to its life on the AMEX and LSE. Forbes Magazine named it as one of the Top 20 fastest growing companies in China, and the recent secondary London listing was claimed to be three times oversubscribed (Bodisen raised £12 million). The cash is earmarked for the construction of two new manufacturing plants, one in Helongjiang and the other in Xinjiang and also for purchasing raw materials and working capital. In January this year China also added a boost to Bodisen's business by eliminating a 15.5% agricultural tax on farm output as part of wider reforms to encourage greater productivity and output from China's agricultural industry to meet growing needs of the domestic economy. However, this weekend the NY Post raised concerns over Bodisen's business, the lack of analyst coverage, and the apparent lack of transparency of the company's auditors and US broker. What the NY Post forgot to mention was that London based Charles Stanley Securities have written a note on the company too, but this is only available to institutional investors in the UK. Perhaps Bodisen should consider having an independant research note written to quell the critics? Bodisen originally reversed into an OTCBB company a few years ago and then moved onto the American Stock Exchange main list last year. The secondary listing in London was an attempt to broaden the companies shareholder base and bring in some institutional support - a look at the volumes traded in New York compared to London quickly reveals that this stock is held by a large number of retail investors in the United States. Bodisen appears as a very simple business selling an ordinary product into an extraordinary market. However, we spoke to some investors who have visited Bodisen's operations in China, and the impression was that the company is anything but simplistic: Bosidens operations actually incorporates a high level of sophistication, modern factories, and the company also has a sound understanding of the importance of marketing and brand awareness. Going forward Bodisen has net cash in excess of USD $20 million, a rapidly expanding market to sell its products into and the potential to aggressively grow at home and abroad. On the flip side the company is trading on an high earnings ratio, so any slip ups could be severly punished, as was shown today when a little negative press comment created a severe drop. |
Posted at 19/5/2006 15:13 by cimbom Stocks >> NEWS Bodisen Biotech Hosted Institutional Investors in Yangling, Management to Conduct Investor Meetings in New York NEW YORK--(BUSINESS WIRE)--May 19, 2006-- Bodisen Biotech, Inc., (AMEX:BBC, London AIM:BODI, website: www.bodisen.com) the first China-based environmentally friendly bio fertilizer company listed on a US stock exchange, and dually listed in London, today announced that the Bodisen management team, led by Chairman and CEO Karen Qiong Wang, hosted visits by institutional investors at the company's Yangling headquarters in China on May 18, 2006. The visit was joined by the company's board members and legal counsel from the US. The visitors toured Bodisen's facilities as well as conducted due diligence meetings with management. The Governor of Shaanxi Province also met with members of the delegation. Bodisen's management will be in New York during the week of May 22, 2006 to meet with other institutional investors. The company's Chairman and CEO Karen Qiong Wang and President Bo Chen will provide an overview of the company's business and operations and its financial results. Bodisen has reported record earnings for the first quarter of 2006 and has reaffirmed 2006 earnings guidance. A copy of the company's updated investor presentation will be available on the company's website at www.bodisen.com starting on May 22, 2006. Institutional investors may contact The Piacente Group, Bodisen's U.S. investor relations counsel, at 212-481-2050 regarding the company's meeting schedules in New York. About Bodisen Biotech, Inc. A Delaware company, Bodisen is headquartered in the city of Yang Ling, Shaanxi Province, China's agricultural hub. The Bodisen brand is a highly recognized fertilizer brand in China. Its environmentally friendly "green" products support the mandate of the Chinese government to increase crop yields for the purpose of decreasing China's dependency on food imports. Utilizing proprietary agricultural technologies, Bodisen sells over 60 packaged products, broken down into four product categories: Organic Compound Fertilizer; Organic Liquid Fertilizer; Pesticides & Insecticides, and agricultural raw materials. Bodisen's organic fertilizers can be absorbed by plants within 48 hours and enrich soil conditions. These products address grains, vegetables, and fruit crops and have been proven to increase crop yields by 10% to 35% while being environmentally friendly. Among China's population of 1.3 billion, approximately 900 million are farmers whose incomes depend on their crop yields. With approximately 600 (and growing) nationwide distribution centers, Bodisen has experienced rapid growth in its existing business. Safe Harbor Statement This press release may contain forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on the current expectations or beliefs of Bodisen Biotech, Inc. management and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Source: Bodisen Biotech, Inc. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
